Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cochrane on EDMA for Bladder Cancer Treatment

Cochrane; 2017 Sep 12; Jung, Gudeloglu, et al

Using electromotive drug administration to administer intravesical mitomycin may delay the time to recurrence in some patients with non-muscle invasive bladder cancer, according to a Cochrane review of 3 studies involving 672 individuals. The impact of serious adverse events is not certain, however. Among the findings:

  • It is not known whether using an electrical current to give a course of mitomycin after endoscopic surgery is better or worse than Bacillus Calmette-Guérin (BCG) or mitomycin without electrical current.
  • Mitomycin with electrical current and BCG given over a longer time period may delay tumor recurrence and spread better than BCG alone.
  • Giving 1 dose of mitomycin with electrical current before endoscopic surgery may be work better than doing the same without electric current after surgery.
  • It also may work better than surgery alone without further treatment.

Citation:

Jung J, Gudeloglu A, Kiziloz H, et al. Intravesical electromotive drug administration for non-muscle invasive bladder cancer. Cochrane Database of Systematic Reviews. 2017, Issue 9. Art. No.: CD011864. doi:10.1002/14651858.CD011864.pub2.

Must Reads in Clinical Guidelines

ASCO Guideline on Alcohol Consumption and Cancer, J Clin Oncol; 2018 Jan; LoConte, Brewster, et al

Guideline on Platelet Transfusion in Ca Patients, J Clin Oncol; ePub 2017 Nov 28; Schiffer, et al

Guideline on Preventing VTE in Pediatric Cancer, J Thromb Haemost; ePub 2017 Nov 27; Tullius, et al

ASCO Updates Guideline on Role of BMAs in BC, J Clin Oncol; ePub 2017 Oct 16; Van Poznak, et al

Cochrane on Heparin Impact in People with Cancer , Cochrane; 2017 Sep 11; Akl, Kahale, et al